Technical Analysis for XRTX - Xortx Therapeutics Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 3.80% | |
180 Bullish Setup | Bullish Swing Setup | 3.80% | |
Wide Bands | Range Expansion | 3.80% | |
Overbought Stochastic | Strength | 3.80% | |
Narrow Range Bar | Range Contraction | 10.81% | |
Wide Bands | Range Expansion | 10.81% | |
Overbought Stochastic | Strength | 10.81% | |
Wide Bands | Range Expansion | 9.33% | |
Overbought Stochastic | Strength | 9.33% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 13.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Bullish 180 Entry | 22 minutes ago |
Rose Above Previous Day's High | 22 minutes ago |
Up 3% | 22 minutes ago |
Up 2% | 22 minutes ago |
Up 1% | 22 minutes ago |
Get this analysis on your stocks daily!
- Earnings date: 2023-11-10
Xortx Therapeutics Inc Description
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.25 |
52 Week Low | 0.33 |
Average Volume | 37,251 |
200-Day Moving Average | 0.947 |
50-Day Moving Average | 1.236 |
20-Day Moving Average | 2.192 |
10-Day Moving Average | 3.612 |
Average True Range | 0.341 |
RSI (14) | 78.49 |
ADX | 49.29 |
+DI | 54.730 |
-DI | 7.476 |
Chandelier Exit (Long, 3 ATRs) | 3.228 |
Chandelier Exit (Short, 3 ATRs) | 1.392 |
Upper Bollinger Bands | 5.348 |
Lower Bollinger Band | -0.965 |
Percent B (%b) | 0.78 |
BandWidth | 288.037 |
MACD Line | 0.870 |
MACD Signal Line | 0.719 |
MACD Histogram | 0.151 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.355 | ||||
Resistance 3 (R3) | 4.317 | 4.143 | 4.288 | ||
Resistance 2 (R2) | 4.143 | 4.040 | 4.163 | 4.265 | |
Resistance 1 (R1) | 4.047 | 3.976 | 4.095 | 4.085 | 4.242 |
Pivot Point | 3.873 | 3.873 | 3.898 | 3.893 | 3.873 |
Support 1 (S1) | 3.777 | 3.770 | 3.825 | 3.815 | 3.658 |
Support 2 (S2) | 3.603 | 3.706 | 3.623 | 3.635 | |
Support 3 (S3) | 3.507 | 3.603 | 3.613 | ||
Support 4 (S4) | 3.545 |